Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common Parkinson's pill help treat wet AMD?

NCT ID NCT03022318

Disease control Sponsor: Snyder, Robert W., M.D., Ph.D., P.C. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial tested carbidopa-levodopa (Sinemet), a drug usually used for Parkinson's disease, in 20 people with wet age-related macular degeneration (AMD). The goal was to see if the drug is safe and can improve vision or reduce retinal swelling. Participants took the pill for a short time, and researchers measured changes in eyesight and eye scans.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
carbidopa-levodopa (Sinemet)
What this could lead to
If it works, this could point toward a new oral treatment for wet AMD, potentially reducing the need for frequent eye injections.
What could go wrong
This is a very small, early-phase trial with only 20 participants. The drug may not improve vision or could cause side effects like nausea or dizziness. Results may not apply to everyone with AMD.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

20 people

The number who actually took part.

Started

May 2017

Finished

May 2020

Lead sponsor

An individual researcher

The lead sponsor is a named person rather than an organisation.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. A diagnosis of AMD with choroidal neovascularization (CNV) in one eye; 2. Not previously treated with anti-VEGF injections; 3. Normal or dry AMD of any grade in the second eye; 4. Age 50-85 years; 5. Willingness to maintain AREDS vitamin supplements throughout the study, or remain off these supplements for the duration of the study, if not taking them prior to the study; 6. Signed Informed Consent. \- Exclusion Criteria: 1. Any current use of L-DOPA containing medication or dopamine agonist medication, or any planned use of any of these agents, except for study medication, during the study; 2. Concurrent use of monoamine oxidase (MAO) inhibitors; 3. Any eye condition, disease, or history of trauma in either eye, which can impair vision, except cataract or cataract surgery; 4. Best Corrected Visual Acuity (BCVA )worse than 20/160 in the better eye; 5. Wet AMD in the second eye; 6. Neurologic conditions which can impair vision; 7. Parkinson's Disease; 8. Significant orthostatic hypotension, defined as a drop in systolic blood pressure, immediately upon changing from the supine to standing position, of \>19 mmHg, or a symptomatic drop in systolic blood pressure, immediately upon changing from the supine to standing position; 9. Significant ECG abnormalities, as judged by the Investigator; 10. Estimated glomerular filtration rate (eGFR) \<20 ml/min; 11. Liver enzymes \>3 X the upper limit of normal; 12. HbA1C \>9.0; 13. Any other significant lab abnormalities, as judged by the Investigator; 14. Women of childbearing potential; 15. Known retinal hemorrhage; 16. Subjects who are not fluent in English. \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Age-related macular degeneration are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

age-related macular degeneration macular degeneration wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Age-related macular degeneration

Contacts and locations

Locations

  • Robert W Snyder, MD, PhD, PC

    Tucson, Arizona, 85712, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.